MACROGENICS, INC. Operating Lease Right-of-Use Assets
MACROGENICS, INC. (MGNX) had Operating Lease Right-of-Use Assets of $21.14 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset $21.14M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $22.48M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $21.78M; Operating Lease, Right-of-Use Asset as first filed $22.89M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $23.30M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $21.14M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $22.48M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $21.78M 10-Q · filed 2026-08-14 | $22.89M 10-K · filed 2026-03-09 |
| 2025-09-30 | $23.30M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $23.71M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $24.11M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $24.51M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $22.01M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $22.62M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $23.23M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $23.85M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $24.63M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $25.50M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $26.39M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $27.34M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $16.61M 10-K · filed 2023-03-15 | $16.60M 10-K · filed 2022-02-24 |
| 2020-12-31 | $19.30M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $20.20M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $20.90M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $17.10M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $17.70M 10-Q · filed 2019-05-01 | |
| 2019-01-01 | $16.40M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |